Board member
Education: MD (Candidate of Medicine) 1982 and PhD 1997, University of Southern Denmark.
Background: Danish Board Authorization in Oncology 1993 (Specialist in Medical Oncology and Radiotherapy). Consultant 1999, professor 2008. He has published more than 280 peer-reviewed articles (H-factor 56) in prestigious journals and he serves as co-editor and reviewer for several oncology journals. He is co-author of ESMO (European) guidelines 2012 and 2016 guidelines in colorectal cancer and ESMO guidelines 2023 in pancreatic cancer. Most recently he planned, presented and published a Danish randomized trial in chemo-refractory metastatic colorectal cancer (Danish Lonsurf trial).
Other ongoing assignments: Professor & consultant in GI-oncology, Dept. of Oncology, OUH & Professor, USD.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
0 shares, 0 TO2 warrants, 0 TO3 warrants and 0 Incentive warrants.